CAM
TVTX icon

Cormorant Asset Management’s Travere Therapeutics TVTX Stock Holding History

Cormorant Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-350,000
Closed -$8.49M – 86
2021
Q3 		$8.49M Buy
+350,000
New +$6.43M 0.34% 57

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cormorant Asset Management's TVTX Position: Q4 2021 in Review

Cormorant Asset Management sold out of Travere Therapeutics (TVTX) in Q4 2021, closing a stake of 350,000 shares — an estimated $8.49M sold.

Cormorant Asset Management first reported a position in TVTX in Q3 2021 and held it in 1 quarter. The position peaked at $8.49M in Q3 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q4 2021.

  • Cormorant Asset Management reported no remaining Travere Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 350,000 Travere Therapeutics shares in Q4 2021, an estimated $8.49M.
  • Cormorant Asset Management first reported a position in Travere Therapeutics in Q3 2021 and held it in 1 quarter.
  • Cormorant Asset Management's Travere Therapeutics position peaked at $8.49M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.